Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Immuneering CorpIMRX · Entity 5884 | Director | June 11, 2026 | June 11, 2026 |
| Notable Labs, Ltd.NTBL · Entity 87239 | Director | May 08, 2024 | May 10, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Immuneering Corp
Report date June 11, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $4.12 · Expires 2036-06-11 | Direct | 33,350 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 33,350 · Balance 33,350 F1: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 11, 2026, and will be fully vested and exercisable on June 11, 2027, or the date of the 2027 annual meeting of stockholders, whichever comes first. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 11, 2026, and will be fully vested and exercisable on June 11, 2027, or the date of the 2027 annual meeting of stockholders, whichever comes first.
Notable Labs, Ltd.
Report date May 08, 2024 · Filed May 10, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 40,247 |
Reported balance
After 2024-05-08 transaction · row 1
1 source rowRow 1 · 2024-05-08 · Grant · Acquired 40,247 · Balance 40,247 F1: Grant of restricted shares vesting in two equal annual installments from the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted shares vesting in two equal annual installments from the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 11, 2026 21:23 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 33,350 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0001790340-26-000064 · wk-form4_1781213003.xml · derivative · entry 1 Feinberg Peter · CIK 0001870076 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,350 Underlying: Class A Common Stock · 33,350 shares Expires 2036-06-11 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 11, 2026, and will be fully vested and exercisable on June 11, 2027, or the date of the 2027 annual meeting of stockholders, whichever comes first. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 13:10 UTC | Immuneering Corp IMRX · Entity 5884 | PurchaseClass A Common Stock | 20,000 | $4.35 | $86,904.00 |
DisclosureSEC source: 0001790340-26-000008 · wk-form4_1768396231.xml · nonDerivative · entry 4 Feinberg Peter · CIK 0001870076 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · General Partner of S4K Investments LLC. Disclosed balance after: 135,441 F1 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $4.315 to $4.38. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price. Read SEC document |
| January 01, 2026 Filed Jan 2, 2026 21:50 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 7,888 | $0.00 Strike: $6.58 | $0.00 |
DisclosureSEC source: 0001790340-26-000002 · wk-form4_1767390602.xml · derivative · entry 1 Feinberg Peter · CIK 0001870076 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,888 Underlying: Class A Common Stock · 7,888 shares Expires 2036-01-01 F1 · security: Pursuant to the Immuneering Corporation Non-Employee Director Compensation Program (the "Compensation Program"), the reporting person elected to receive this stock option in lieu of receiving the cash Base Retainer (as defined in the Compensation Program). F2 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the shares subject to the option upon the reporting person completing three months of continuous service as a Non-Employee Director (as defined in the Compensation Program) following the grant date, such that the fourth and final installment will vest and become exercisable on the first anniversary of the grant date, subject in each case to such continuous service. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 12:56 UTC | Immuneering Corp IMRX · Entity 5884 | PurchaseClass A Common Stock | 7,500 | $6.67 | $50,025.00 |
DisclosureSEC source: 0001790340-25-000127 · wk-form4_1759841769.xml · nonDerivative · entry 1 Feinberg Peter · CIK 0001870076 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 156,766 Read SEC document |
| September 30, 2025 Filed Oct 1, 2025 12:59 UTC | Immuneering Corp IMRX · Entity 5884 | PurchaseClass A Common Stock | 7,500 | $7.03 | $52,730.25 |
DisclosureSEC source: 0001790340-25-000119 · wk-form4_1759323577.xml · nonDerivative · entry 1 Feinberg Peter · CIK 0001870076 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 149,266 F1 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $7.0049 to $7.055. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price. Read SEC document |
| September 29, 2025 Filed Sep 30, 2025 13:00 UTC | Immuneering Corp IMRX · Entity 5884 | PurchaseClass A Common Stock | 5,000 | $7.18 | $35,900.00 |
DisclosureSEC source: 0001790340-25-000117 · wk-form4_1759237255.xml · nonDerivative · entry 1 Feinberg Peter · CIK 0001870076 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 141,766 Read SEC document |
| June 18, 2025 Filed Jun 23, 2025 13:09 UTC | Immuneering Corp IMRX · Entity 5884 | PurchaseClass A Common Stock | 25,000 | $2.53 | $63,187.50 |
DisclosureSEC source: 0001790340-25-000083 · wk-form4_1750684190.xml · nonDerivative · entry 1 Feinberg Peter · CIK 0001870076 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,766 F1 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $2.07 to $2.96. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price. Read SEC document |
| June 13, 2025 Filed Jun 16, 2025 13:04 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 33,350 | $0.00 Strike: $1.90 | $0.00 |
DisclosureSEC source: 0001790340-25-000069 · wk-form4_1750079056.xml · derivative · entry 1 Feinberg Peter · CIK 0001870076 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,350 Underlying: Class A Common Stock · 33,350 shares Expires 2035-06-13 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 13, 2025, and will be fully vested and exercisable on June 13, 2026, or the date of the 2026 annual meeting of stockholders, whichever comes first. Read SEC document |
| January 01, 2025 Filed Jan 2, 2025 21:12 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 23,485 | $0.00 Strike: $2.20 | $0.00 |
DisclosureSEC source: 0001790340-25-000007 · wk-form4_1735852326.xml · derivative · entry 1 Feinberg Peter · CIK 0001870076 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,485 Underlying: Class A Common Stock · 23,485 shares Expires 2035-01-01 F1 · security: Pursuant to the Immuneering Corporation Non-Employee Director Compensation Program (the "Compensation Program"), the reporting person elected to receive this stock option in lieu of receiving the cash Base Retainer (as defined in the Compensation Program). F2 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the shares subject to the option upon the reporting person completing three months of continuous service as a Non-Employee Director (as defined in the Compensation Program) following the grant date, such that the fourth and final installment will vest and become exercisable on the first anniversary of the grant date, subject in each case to such continuous service. Read SEC document |
| June 12, 2024 Filed Jun 13, 2024 20:20 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 33,350 | $0.00 Strike: $1.54 | $0.00 |
DisclosureSEC source: 0001628280-24-028057 · wk-form4_1718310005.xml · derivative · entry 1 Feinberg Peter · CIK 0001870076 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,350 Underlying: Class A Common Stock · 33,350 shares Expires 2034-06-12 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 12, 2024, and will be fully vested and exercisable on June 12, 2025, or the date of the 2025 annual meeting of stockholders, whichever comes first. Read SEC document |
| May 08, 2024 Filed May 10, 2024 21:06 UTC | Notable Labs, Ltd. NTBL · Entity 87239 | GrantOrdinary Shares | 40,247 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-009929 · form4.xml · nonDerivative · entry 1 Feinberg Peter · CIK 0001870076 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,247 F1 · price: Grant of restricted shares vesting in two equal annual installments from the date of grant. Read SEC document |
| March 22, 2024 Filed Mar 25, 2024 13:13 UTC | Immuneering Corp IMRX · Entity 5884 | PurchaseClass A Common Stock | 25,000 | $2.55 | $63,712.50 |
DisclosureSEC source: 0001790340-24-000042 · wk-form4_1711372421.xml · nonDerivative · entry 1 Feinberg Peter · CIK 0001870076 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,766 F1 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $2.52 to $2.57. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price. Read SEC document |
| March 19, 2024 Filed Mar 19, 2024 23:04 UTC | Immuneering Corp IMRX · Entity 5884 | PurchaseClass A Common Stock | 25,000 | $2.56 | $64,000.00 |
DisclosureSEC source: 0001790340-24-000028 · wk-form4_1710889466.xml · nonDerivative · entry 3 Feinberg Peter · CIK 0001870076 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,766 Read SEC document |
| March 18, 2024 Filed Mar 19, 2024 23:04 UTC | Immuneering Corp IMRX · Entity 5884 | PurchaseClass A Common Stock | 4,976 | $3.05 | $15,201.18 |
DisclosureSEC source: 0001790340-24-000028 · wk-form4_1710889466.xml · nonDerivative · entry 2 Feinberg Peter · CIK 0001870076 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,766 F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $2.9863 to $3.1799. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price. Read SEC document |
| March 18, 2024 Filed Mar 19, 2024 23:04 UTC | Immuneering Corp IMRX · Entity 5884 | PurchaseClass A Common Stock | 45,024 | $2.31 | $103,856.86 |
DisclosureSEC source: 0001790340-24-000028 · wk-form4_1710889466.xml · nonDerivative · entry 1 Feinberg Peter · CIK 0001870076 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,790 F1 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $1.96 to $2.9499. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price. Read SEC document |
| January 24, 2024 Filed Jan 26, 2024 16:05 UTC | Notable Labs, Ltd. NTBL · Entity 87239 | GrantStock Option · Derivative | 9,753 | $0.00 Strike: $1.28 | $0.00 |
DisclosureSEC source: 0001062993-24-001366 · form4.xml · derivative · entry 1 Feinberg Peter · CIK 0001870076 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,753 Underlying: Ordinary Shares · 9,753 shares Expires 2034-01-24 F1 · derivative.exercise_date: Option vests 50% on the first anniversary of date of grant and thereafter in four equal quarterly installments ending on the second anniversary of the date of grant. Read SEC document |
| January 01, 2024 Filed Jan 2, 2024 21:26 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 6,879 | $0.00 Strike: $7.35 | $0.00 |
DisclosureSEC source: 0001790340-24-000002 · wk-form4_1704230750.xml · derivative · entry 1 Feinberg Peter · CIK 0001870076 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,879 Underlying: Class A Common Stock · 6,879 shares Expires 2034-01-01 F1 · security: Pursuant to the Immuneering Corporation Non-Employee Director Compensation Program (the "Compensation Program"), the reporting person elected to receive this stock option in lieu of receiving the cash Base Retainer (as defined in the Compensation Program). F2 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the shares subject to the option upon the reporting person completing three months of continuous service as a Non-Employee Director (as defined in the Compensation Program) following the grant date, such that the fourth and final installment will vest and become exercisable on the first anniversary of the grant date, subject in each case to such continuous service. Read SEC document |
| June 14, 2023 Filed Jun 15, 2023 20:35 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 17,500 | $0.00 Strike: $9.32 | $0.00 |
DisclosureSEC source: 0001790340-23-000035 · wk-form4_1686861302.xml · derivative · entry 1 Feinberg Peter · CIK 0001870076 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 Underlying: Class A Common Stock · 17,500 shares Expires 2033-06-14 F1 · derivative.exercise_date: The option vests and becomes exercisable in substantially equal monthly installments over a one-year period with a vesting commencement date of June 14, 2023, and will be fully vested and exercisable on June 14, 2024, or the date of the 2024 annual meeting of stockholders, whichever comes first. Read SEC document |
| June 21, 2022 Filed Jun 23, 2022 21:06 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 14,200 | $0.00 Strike: $4.63 | $0.00 |
DisclosureSEC source: 0001415889-22-006899 · form4-06232022_020630.xml · derivative · entry 1 Feinberg Peter · CIK 0001870076 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,200 Underlying: Class A Common Stock · 14,200 shares Expires 2032-06-20 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 21, 2022, and will be fully vested and exercisable on June 21, 2023, or the date of the 2023 annual meeting of stockholders, whichever comes first. Read SEC document |
| March 15, 2022 Filed Mar 16, 2022 21:30 UTC | Immuneering Corp IMRX · Entity 5884 | PurchaseClass A Common Stock | 6,667 | $6.75 | $45,002.25 |
DisclosureSEC source: 0001415889-22-003061 · form4-03162022_020302.xml · nonDerivative · entry 1 Feinberg Peter · CIK 0001870076 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,766 F1 · price: This transaction was executed in multiple trades through a broker-dealer at a price of $6.75. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares acquired at such price. Read SEC document |
| September 20, 2021 Filed Sep 21, 2021 21:53 UTC | Immuneering Corp IMRX · Entity 5884 | PurchaseClass A Common Stock | 4,750 | $24.45 | $116,113.75 |
DisclosureSEC source: 0001415889-21-004512 · form4-09212021_020937.xml · nonDerivative · entry 1 Feinberg Peter · CIK 0001870076 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,099 F1 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $23.75 to $24.75. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares acquired at each price. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 21:58 UTC | Immuneering Corp IMRX · Entity 5884 | PurchaseClass A Common Stock | 349 | $21.25 | $7,416.25 |
DisclosureSEC source: 0001415889-21-004407 · form4-09152021_020922.xml · nonDerivative · entry 2 Feinberg Peter · CIK 0001870076 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 349 F2 · price: This transaction was executed in multiple trades through a broker-dealer at a price of $21.25. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares acquired at each price. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 21:58 UTC | Immuneering Corp IMRX · Entity 5884 | PurchaseClass A Common Stock | 5,750 | $21.51 | $123,697.45 |
DisclosureSEC source: 0001415889-21-004407 · form4-09152021_020922.xml · nonDerivative · entry 1 Feinberg Peter · CIK 0001870076 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · General Partner of PF Associates L.P. Disclosed balance after: 392,242 F1 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $21.08 to $22.00. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares acquired at each price. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 10:06 UTC | Immuneering Corp IMRX · Entity 5884 | ConversionSeries B Preferred Stock · Derivative | 30,646 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-099742 · tm2123807-9_4seq1.xml · derivative · entry 12 Feinberg Peter · CIK 0001870076 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Class A Common Stock · 30,646 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F4 · ownership.nature: Mr. Feinberg is a General Partner of S4K Investments LLC. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 10:06 UTC | Immuneering Corp IMRX · Entity 5884 | ConversionSeries B Preferred Stock · Derivative | 30,646 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-099742 · tm2123807-9_4seq1.xml · derivative · entry 11 Feinberg Peter · CIK 0001870076 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Class A Common Stock · 30,646 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F3 · ownership.nature: Mr. Feinberg is a General Partner of PEF LLC. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 10:06 UTC | Immuneering Corp IMRX · Entity 5884 | ConversionSeries B Preferred Stock · Derivative | 30,646 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-099742 · tm2123807-9_4seq1.xml · derivative · entry 10 Feinberg Peter · CIK 0001870076 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Class A Common Stock · 30,646 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F2 · ownership.nature: Mr. Feinberg is a General Partner of PF Associates L.P. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 10:06 UTC | Immuneering Corp IMRX · Entity 5884 | ConversionSeries A Preferred Stock · Derivative | 51,462 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-099742 · tm2123807-9_4seq1.xml · derivative · entry 9 Feinberg Peter · CIK 0001870076 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Class A Common Stock · 51,462 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F4 · ownership.nature: Mr. Feinberg is a General Partner of S4K Investments LLC. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 10:06 UTC | Immuneering Corp IMRX · Entity 5884 | ConversionSeries A Preferred Stock · Derivative | 92,509 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-099742 · tm2123807-9_4seq1.xml · derivative · entry 8 Feinberg Peter · CIK 0001870076 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Class A Common Stock · 92,509 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F3 · ownership.nature: Mr. Feinberg is a General Partner of PEF LLC. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 10:06 UTC | Immuneering Corp IMRX · Entity 5884 | ConversionSeries A Preferred Stock · Derivative | 102,926 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-099742 · tm2123807-9_4seq1.xml · derivative · entry 7 Feinberg Peter · CIK 0001870076 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Class A Common Stock · 102,926 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F2 · ownership.nature: Mr. Feinberg is a General Partner of PF Associates L.P. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 10:06 UTC | Immuneering Corp IMRX · Entity 5884 | PurchaseClass A Common Stock | 33,333 | $15.00 | $499,995.00 |
DisclosureSEC source: 0001104659-21-099742 · tm2123807-9_4seq1.xml · nonDerivative · entry 6 Feinberg Peter · CIK 0001870076 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Foonote Disclosed balance after: 115,441 F4 · ownership.nature: Mr. Feinberg is a General Partner of S4K Investments LLC. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 10:06 UTC | Immuneering Corp IMRX · Entity 5884 | ConversionClass A Common Stock | 82,108 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-099742 · tm2123807-9_4seq1.xml · nonDerivative · entry 5 Feinberg Peter · CIK 0001870076 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Foonote Disclosed balance after: 82,108 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F4 · ownership.nature: Mr. Feinberg is a General Partner of S4K Investments LLC. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 10:06 UTC | Immuneering Corp IMRX · Entity 5884 | PurchaseClass A Common Stock | 129,167 | $15.00 | $1,937,505.00 |
DisclosureSEC source: 0001104659-21-099742 · tm2123807-9_4seq1.xml · nonDerivative · entry 4 Feinberg Peter · CIK 0001870076 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Foonote Disclosed balance after: 476,568 F3 · ownership.nature: Mr. Feinberg is a General Partner of PEF LLC. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 10:06 UTC | Immuneering Corp IMRX · Entity 5884 | ConversionClass A Common Stock | 123,155 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-099742 · tm2123807-9_4seq1.xml · nonDerivative · entry 3 Feinberg Peter · CIK 0001870076 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Foonote Disclosed balance after: 347,401 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F3 · ownership.nature: Mr. Feinberg is a General Partner of PEF LLC. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 10:06 UTC | Immuneering Corp IMRX · Entity 5884 | PurchaseClass A Common Stock | 129,167 | $15.00 | $1,937,505.00 |
DisclosureSEC source: 0001104659-21-099742 · tm2123807-9_4seq1.xml · nonDerivative · entry 2 Feinberg Peter · CIK 0001870076 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Foonote Disclosed balance after: 386,492 F2 · ownership.nature: Mr. Feinberg is a General Partner of PF Associates L.P. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 10:06 UTC | Immuneering Corp IMRX · Entity 5884 | ConversionClass A Common Stock | 133,572 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-099742 · tm2123807-9_4seq1.xml · nonDerivative · entry 1 Feinberg Peter · CIK 0001870076 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Foonote Disclosed balance after: 257,325 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F2 · ownership.nature: Mr. Feinberg is a General Partner of PF Associates L.P. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.